Treatment of superficial vein thrombosis with intermediate dose of tinzaparin: A real word cohort study – The SeVEN EXTension study
Ημερομηνία
2021Γλώσσα
en
Λέξη-κλειδί
Επιτομή
Background: To assess the treatment of superficial vein thrombosis (SVT) with intermediate dose of tinzaparin in a setting of real world practice. Methods: Prospective observational study of consecutive patients treated by vascular physicians in the private sector with tinzaparin (131 IU/Kg) once daily. Treatment duration was at the treating physician’s discretion. The outcomes of the study were symptomatic venous thromboembolism, extension of thrombus and bleeding complications. Results: 660 patients were included and followed up for at least 3 months. Median duration of treatment was 30 days (14–120). History of prior deep vein thrombosis (HR 2.77; 95% CI= 1.18–6.49; p = 0.018) and current SVT above the knee (HR1.84; 95% CI = 1.33–3.53; p = 0.0002) were associated with prolonged treatment duration. Primary efficacy outcomes occurred in 20 (3%) patients. The median time to the event was 24 (6–92) days and was not related to treatment duration. Conclusions: Tinzaparin at intermediate dose is an effective and safe treatment for SVT. © The Author(s) 2021.
Collections
Showing items related by title, author, creator and subject.
-
Recurrence of superficial vein thrombosis in patients with varicose veins
Karathanos C., Spanos K., Saleptsis V., Tsezou A., Kyriakou D., Giannoukas A.D. (2016)Objective: To investigate which factors other than history of superficial vein thrombosis (SVT) are associated with recurrent spontaneous SVT episodes in patients with varicose veins (VVs). Materials and methods: Patients ... -
Advancements in the Treatment of Cerebrovascular Complications of Cancer
Aloizou A.-M., Siokas V., Mentis A.-F.A., Dastamani M., Sokratous M., Xiromerisiou G., Mitsias P.D., Hadjigeorgiou G.M., Dardiotis E. (2020)Purpose of review: To present the new guidelines and therapeutic options regarding cerebrovascular complications of cancer, mainly ischemic stroke, cerebral venous thrombosis (CVT), and leptomeningeal carcinomatosis (LMC). ... -
Low-molecular-weight heparin for prevention of thrombosis: Inverted role
Dailiana, Z. H.; Malizos, K. N.; Varitimidis, S.; Hantes, M.; Basdekis, G.; Rigopoulos, N. (2007)BACKGROUND: Heparin induced thrombosis (HIT) after low-molecular-weight (LMWH) administration for thrombosis prevention is a limb and life threatening condition. METHODS: Two previously healthy individuals, with nonviable ...